medigraphic.com
ISSN 0188-2198 (Impreso)

2017, Número 4

<< Anterior Siguiente >>

Rev Mex Cardiol 2017; 28 (4)


Desfibrilador implantable subcutáneo: una alternativa terapéutica para la prevención de la muerte súbita cardiaca

Rico-Mesa JS, Duque L, Díaz JC, Velásquez JE, Aristizábal J, Marín J, Uribe W, Duque M

Idioma: Ingles.
Referencias bibliográficas: 49
Paginas: 189-199
Archivo PDF: 390.39 Kb.


RESUMEN

El desfibrilador cardiaco implantable transvenoso (DCI-T) se considera actualmente el tratamiento estándar para la prevención de la muerte súbita cardiaca en pacientes con enfermedad cardiaca estructural o canalopatías. Sin embargo, el uso de estos dispositivos se asocia con un aumento significativo de complicaciones a corto y largo plazo, principalmente relacionadas con derivaciones intravasculares. El desfibrilador cardiaco implantable subcutáneo (DCI-S) es una alternativa novedosa para pacientes de alto riesgo susceptibles a complicaciones intravasculares, con una eficacia similar al DCI-T. Se espera que varios ensayos clínicos en curso que involucran al DCI-S brinden información adicional sobre seguridad, uso y beneficios en el entorno clínico.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med. 1999; 341 (25): 1882-1890.

  2. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996; 335 (26): 1933-1940.

  3. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002; 346 (12): 877.-883.

  4. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJ et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Rev Esp Cardiol (Engl Ed). 2016; 69 (12): 1167.

  5. Rowley CP, Gold MR. Subcutaneous implantable cardioverter defibrillator. Circ Arrhythm Electrophysiol. 2012; 5 (3): 587-593.

  6. Mirowski M, Reid PR, Mower MM, Watkins L, Gott VL, Schauble JF et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med. 1980; 303 (6): 322-324.

  7. Masoudi FA, Ponirakis A, de Lemos JA, Jollis JG, Kremers M, Messenger JC et al. Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries. J Am Coll Cardiol. 2017; 69 (11): 1427-1450. https://www.ncbi.nlm.nih.gov/pubmed/28025065

  8. van Welsenes GH, Borleffs CJ, van Rees JB, Atary JZ, Thijssen J, van der Wall EE et al. Improvements in 25 years of implantable cardioverter defibrillator therapy. Neth Heart J. 2011; 19 (1): 24-30.

  9. MADIT-II | Boston Scientific [Internet]. [Cited 2016 Apr 28]. Available from: https://www.bostonscientific.com/en-US/medical-specialties/electrophysiology/clinical-science/tachyarrhythmia/MADIT-II.html

  10. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med. 2005; 352 (3): 225-237.

  11. Ezzat VA, Lee V, Ahsan S, Chow AW, Segal O, Rowland E et al. A systematic review of ICD complications in randomized controlled trials versus registries: is our ‘real-world’ data an underestimation? Open Heart. 2015; 2 (1): e000198.

  12. Kremers MS, Hammill SC, Berul CI, Koutras C, Curtis JS, Wang Y et al. The National ICD Registry Report: Version 2.1 including leads and pediatrics for years 2010 and 2011. Heart Rhythm. 2013; 10 (4): e59-65.

  13. Kleemann T, Becker T, Doenges K, Vater M, Senges J, Schneider S et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. Circulation. 2007; 115 (19): 2474-2480.

  14. Ferrari P, Giofrè F, De Filippo P. Intermuscular pocket for subcutaneous implantable cardioverter defibrillator: Single-center experience. J Arrhythm. 2016; 32 (3): 223-226.

  15. Winter J, Siekiera M, Shin DI, Meyer C, Kröpil P, Clahsen H, O’Connor S. Intermuscular technique for implantation of the subcutaneous implantable cardioverter defibrillator: long-term performance and complications. Europace. 2017; 19 (12): 2036-2041.

  16. doi: 10.1093/europace/euw297

  17. Migliore F, Allocca G, Calzolari V, Crosato M, Facchin D, Daleffe E et al. Intermuscular two-incision technique for subcutaneous implantable cardioverter defibrillator implantation: results from a multicenter registry: intermuscular two-incision technique for S-ICD implantation. Pacing Clin Electrophysiol. 2017; 40 (3): 278-285.

  18. Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP et al. Reduction in inappropriate therapy and mortality through ICD Programming. N Engl J Med. 2012; 367 (24): 2275-2283.

  19. Ip JE, Wu MS, Kennel PJ, Thomas G, Liu CF, Cheung JW et al. Eligibility of pacemaker patients for subcutaneous implantable cardioverter defibrillators: S-ICD candidacy among ventricularly paced patients. J Cardiovasc Electrophysiol. 2017; 28 (5): 544-548.

  20. Poole JE, Gold MR. Who should receive the subcutaneous implanted defibrillator?: The subcutaneous implantable cardioverter defibrillator (ICD) should be considered in all ICD patients who do not require pacing. Circ Arrhythm Electrophysiol. 2013; 6 (6): 1236-1244; discussion 1244-1245.

  21. Weinstock J, Bader YH, Maron MS et al. Subcutaneous implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy: an initial experience. J Am Heart Assoc. 2016; 5 (2): e002488.

  22. Burke MC, Gold MR, Knight BP, Barr CS, Theuns DA, Boersma LV et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE study and EFFORTLESS registry. J Am Coll Cardiol. 2015; 65 (16): 1605-1615.

  23. Dhamija RK, Tan H, Philbin E, Mathew RO, Sidhu MS, Wang J et al. Subcutaneous implantable cardioverter defibrillator for dialysis patients: a strategy to reduce central vein stenoses and infections. Am J Kidney Dis. 2015; 66 (1): 154-158.

  24. El-Chami MF, Levy M, Kelli HM, Casey M, Hoskins MH, Goyal A et al. Outcome of subcutaneous implantable cardioverter defibrillator implantation in patients with end-stage renal disease on dialysis. J Cardiovasc Electrophysiol. 2015; 26 (8): 900-904.

  25. Saxon LA, Hayes DL, Roosevelt GF, Heidenreich PA, Day J, Seth M et al. Long-term outcome after ICD and CRT implantation and influence of remote device follow-upclinical perspective. Circulation. 2010; 122 (23): 2359-2367.

  26. Theuns DA, Crozier IG, Barr CS, Hood MA, Cappato R, Knops RE et al. Longevity of the subcutaneous implantable defibrillator long-term follow-up of the european regulatory trial cohort. Circ Arrhythm Electrophysiol. 2015; 8 (5): 1159-1163.

  27. Clinical Data Surrounding the EMBLEMTM S-ICD System. Boston Scientific [Internet]. [Cited 2016 Aug 19]. Available from: http://www.bostonscientific.com/en-US/products/defibrillators/emblem-s-icd-system/clinical-data.html

  28. Randles DA, Hawkins NM, Shaw M, Patwala AY, Pettit SJ, Wright DJ. How many patients fulfil the surface electrocardiogram criteria for subcutaneous implantable cardioverter-defibrillator implantation? Europace. 2014; 16 (7): 1015-1021.

  29. Ziegelhoeffer T, Siebel A, Markewitz A, Doll N, Bärsch V, Reinartz M et al. Intraoperative defibrillation testing should not be generally abandoned for all icd procedures-a multicenter study on 4,572 consecutive patients. Thorac Cardiovasc Surg. 2016; 64 (08): 679-687.

  30. Okamura H, McLeod CJ, DeSimone CV, Webster TL, Bonnichsen CR, Grogan M et al. Right parasternal lead placement increases eligibility for subcutaneous implantable cardioverter defibrillator therapy in adults with congenital heart disease. Circ J. 2016; 80 (6): 1328-1335.

  31. Weiss R, Knight BP, Gold MR, Leon AR, Herre JM, Hood M et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013; 128 (9): 944-953.

  32. Olde NL, Dabiri AL, Boersma LV, Maass AH, de Groot JR, van Oostrom AJ et al. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. J Am Coll Cardiol. 2012; 60 (19): 1933-1939.

  33. Jarman JWE, Todd DM. United Kingdom national experience of entirely subcutaneous implantable cardioverter-defibrillator technology: important lessons to learn. Europace. 2013; 15 (8): 1158-1165.

  34. Aydin A, Hartel F, Schlüter M, Butter C, Köbe J, Seifert M et al. Shock efficacy of subcutaneous implantable cardioverter-defibrillator for prevention of sudden cardiac death: initial multicenter experience. Circ Arrhythm Electrophysiol. 2012; 5 (5): 913-919.

  35. Wilkoff BL. How to treat and identify device infections. Heart Rhythm. 2007; 4 (11): 1467-1470.

  36. LE KY, Sohail MR, Friedman PA, Uslan DZ, Cha SS, Hayes DL et al. linical predictors of cardiovascular implantable electronic device-related infective endocarditis. Pacing Clin Electrophysiol. 2011; 34 (4): 450-459.

  37. Knops RE, Brouwer TF, Barr CS, Theuns DA, Boersma L, Weiss R et al. The learning curve associated with the introduction of the subcutaneous implantable defibrillator. Europace. 2016; 18 (7): 1010-1015.

  38. Lambiase PD, Barr C, Theuns DA, Knops R, Neuzil P, Johansen JB et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J. 2014; 35 (25): 1657-1665.

  39. Bardy GH, Smith WM, Hood MA, Crozier IG, Melton IC, Jordaens L et al. An entirely subcutaneous implantable cardioverter–defibrillator. N Engl J Med. 2010; 363 (1): 36-44.

  40. Gold MR, Theuns DA, Knight BP, Sturdivant JL, Sanghera R, Ellenbogen KA et al. Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous icd arrhythmia detection algorithms: the START Study. J Cardiovasc Electrophysiol. 2012; 23 (4): 359-366.

  41. Neuzil P, Reddy VY, Merkely B, Geller L, Molnar L, Bednarek J et al. Implantable intravascular defibrillator: Defibrillation thresholds of an intravascular cardioverter-defibrillator compared with those of a conventional ICD in humans. Heart Rhythm. 2014; 11 (2): 210-215.

  42. Kooiman KM, Knops RE, Olde Nordkamp L, Wilde AA, de Groot JR. Inappropriate subcutaneous implantable cardioverter-defibrillator shocks due to T-wave oversensing can be prevented: Implications for management. Heart Rhythm. 2014; 11 (3): 426-434.

  43. Olde Nordkamp LR, Warnaars JL, Kooiman KM, de Groot JR, Rosenmöller BR, Wilde AA et al. Which patients are not suitable for a subcutaneous ICD: incidence and predictors of failed QRS-t-wave morphology screening: T-Wave analysis for the subcutaneous ICD. J Cardiovasc Electrophysiol. 2014; 25 (5): 494-949.

  44. Lewis GF, Gold MR. Safety and efficacy of the subcutaneous implantable defibrillator. J Am Coll Cardiol. 2016; 67 (4): 445-454.

  45. Ruwald A-C, Schuger C, Moss AJ, Kutyifa V, Olshansky B, Greenberg H et al. Mortality reduction in relation to implantable cardioverter defibrillator programming in the multicenter automatic defibrillator implantation trial-reduce inappropriate therapy (MADIT-RIT). Circ Arrhythm Electrophysiol. 2014; 7 (5): 785-792.

  46. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015; 36 (41): 2793-2867.

  47. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2013; 62 (16): e147-239.

  48. Bennett M, Parkash R, Nery P, Sénéchal M, Mondesert B, Birnie D et al. Canadian Cardiovascular Society/Canadian Heart Rhythm Society 2016 Implantable Cardioverter-Defibrillator Guidelines. Can J Cardiol. 2017; 33 (2): 174-188.

  49. Olde Nordkamp LR, Knops RE, Bardy GH, Blaauw Y, Boersma LV, Bos JS et al. Rationale and design of the PRAETORIAN trial: A Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy. Am Heart J. 2012; 163 (5): 753-760.e2.




2020     |     www.medigraphic.com